Ceribell
Sunnyvale, California, United States · Healthcare, Health Care
Ceribell, Inc., the developer of the first AI-powered point-of-care EEG diagnostic system, is revolutionizing seizure management in acute care. Ceribell’s mission is to make EEG diagnostics widely available, more efficient, and more cost-effective, to improve the detection and treatment of neurological conditions.
Key facts
- Headquarters
- Sunnyvale, California, United States
- Employees
- Unknown
- Industries
- Healthcare, Health Care
- Status
- Public (CBLL)
- Website
- www.ceribell.com
- Company page
Recent activity at Ceribell
- : Ceribell launched its Delirium Monitoring Solution to enhance brain monitoring capabilities.
- : SEC 8-K (5.02): On July 28, 2026, CeriBell, Inc. made significant changes to its Board of Directors. William W. Burke and Joseph M. Taylor resigned from their positions as Class I directors, but were immediately re-elected to Class II and Class III director positions, respectively, in a move to rebalance the Board's membership. Additionally, the Board expanded from seven to nine members, electing Sharon L. O’Keefe and Thomas A. West to fill the new positions as Class I directors. Each new director will receive annual cash compensation and restricted stock units based on a $300,000 value, with vesting occurring over three years. These appointments aim to strengthen Board representation and governance. The reorganization took effect on the same date, July 28, 2026.
- : SEC 8-K (8.01): On January 5, 2026, Ceribell, Inc. announced via a press release that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution. This designation aims to expedite the development and review process for the innovative device, which is expected to significantly impact the treatment of stroke patients. The press release signifies a pivotal moment for Ceribell as it seeks to enhance its product offerings in the healthcare technology market, thereby improving patient outcomes. A copy of the press release is included as Exhibit 99.1 in the filing.
- : SEC 8-K (5.02): On December 30, 2025, Lucian Iancovici resigned from the Board of Directors of CeriBell, Inc., along with his positions as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee. His resignation is effective as of December 31, 2025, and was communicated to the Board, indicating no disagreements with the company's practices or policies. This change may affect the company's governance structure and could influence strategic decisions given the roles occupied by Mr. Iancovici. The filing includes a resignation letter dated December 30, 2025, as an exhibit.
- : SEC 8-K (1.01): On December 11, 2025, Ceribell, Inc. entered into two material definitive agreements: the Second Amendment to the Standard Industrial/Commercial Multi-Tenant Lease for 11,607 square feet at 625 N. Pastoria Ave., extending the lease term through January 31, 2028 with a monthly rent of $34,821.00, and the First Amendment to the Lease for 15,600 square feet at 360 N. Pastoria Ave., extending this lease also through January 31, 2028 with a monthly rent of $74,147.00. The effective dates of these amendments are December 4, 2025, and December 8, 2025, respectively. These extensions provide Ceribell with stability in its operational locations and financial commitments for the next few years, reflecting ongoing growth and strategic planning.
- : SEC 8-K (8.01): On December 9, 2025, Ceribell, Inc. announced via a press release that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary delirium screening and monitoring solution. This clearance is significant for Ceribell as it allows the company to market and sell its innovative medical solution, which could enhance its product offerings and market positioning. The announcement may lead to increased investment interest and potential partnerships due to the importance of FDA approval in the healthcare industry. The press release is attached as Exhibit 99.1, which provides further details on the clearance and its implications for Ceribell's operations and strategy.
- : SEC 8-K (8.01): On November 24, 2025, Ceribell, Inc. announced via press release that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Clarity® algorithm, which is designed to detect electrographic seizures in newborns, both preterm and older. This significant regulatory achievement is expected to enhance the company's product offerings in the medical technology sector, specifically addressing critical needs in neonatal care. The announcement reflects a strategic advancement for Ceribell in a competitive market focusing on neonatal seizure detection and management.
- : SEC 8-K (8.01): On November 24, 2025, Ceribell, Inc. announced that it received 510(k) clearance from the U.S. Food and Drug Administration for its Clarity Ⓡ algorithm, which is designed to detect electrographic seizures in newborns, both preterm and older. This clearance marks a significant milestone for Ceribell, potentially enhancing its product offerings and positioning in the medical device market. The announcement reflects the company's commitment to improving neonatal care through advanced technologies. The press release is included as Exhibit 99.1 to this filing.
- : CeriBell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing
- : Ceribell, Inc. Appoints Sean Manni as Senior Vice President of Sales
Ceribell funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Venture | $50.0M |
| May 2021 | Venture | $52.5M |
Leadership
- Xingjuan Chao, Executive Officer, Director
- Lucian Iancovici, Director
- Josef Parvizi, Director
- Rebecca Robertson, Director
- Juliet Bakker, Director
- Joseph Taylor, Director
- Brian Price, Vice President of Marketing
- Kristie Rodenbush, Chief People Officer
- Sean Manni, Senior Vice President of Sales
- Joshua Copp, Chief Business Officer
- Scott Blumberg, Executive Officer
Verified email and direct lines for Ceribell’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Ceribell files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Ceribell in the news
- Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System - Yahoo Finance (Aug 03, 2026)
- Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026 - GlobeNewswire (Oct 20, 2026)
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - GlobeNewswire (Oct 28, 2026)
- Ceribell Launches ClarityPro™ AI, Expanding Access to Critical Diagnosis of Electrographic Status Epilepticus - PR Newswire (Oct 30, 2023)
Companies similar to Ceribell
- Oruka Therapeutics · Healthcare, Health Care
- Olema Pharmaceuticals, Inc. · Healthcare, Health Care
- eHealth · Healthcare, Health Care
- iSpecimen · Healthcare, Health Care
- Beam Therapeutics Inc. · Healthcare, Health Care
About Ceribell: questions and answers
What does Ceribell do?
Ceribell, Inc., the developer of the first AI-powered point-of-care EEG diagnostic system, is revolutionizing seizure management in acute care. Ceribell’s mission is to make EEG diagnostics widely available, more efficient, and more cost-effective, to improve the detection and treatment of neurological conditions.
Where is Ceribell headquartered?
Ceribell is headquartered in Sunnyvale, California, United States.
Has Ceribell raised funding?
Yes. Fundz has recorded 2 funding events for Ceribell. The most recent, $50.0M, was in Sep 2022.
Who leads Ceribell?
Brian Price is a Vice President of Marketing at Ceribell.
What is the latest news on Ceribell?
On Nov 02, 2026, Ceribell launched its Delirium Monitoring Solution to enhance brain monitoring capabilities.
Is Ceribell a public company?
Yes. Ceribell is publicly traded under the ticker CBLL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy